Head to Head Analysis: Corium International (CORI) versus Opko Health (OPK)

Corium International (NASDAQ: CORI) and Opko Health (NASDAQ:OPK) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Corium International and Opko Health, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Corium International 0 0 6 0 3.00
Opko Health 0 2 5 0 2.71

Corium International presently has a consensus target price of $13.00, suggesting a potential upside of 29.48%. Opko Health has a consensus target price of $14.21, suggesting a potential upside of 180.36%. Given Opko Health’s higher possible upside, analysts clearly believe Opko Health is more favorable than Corium International.

Institutional and Insider Ownership

89.4% of Corium International shares are owned by institutional investors. Comparatively, 22.9% of Opko Health shares are owned by institutional investors. 46.5% of Corium International shares are owned by company insiders. Comparatively, 40.2% of Opko Health shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Corium International and Opko Health’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Corium International -149.99% -612.73% -64.69%
Opko Health -9.45% -5.17% -3.94%

Risk & Volatility

Corium International has a beta of 1.26, suggesting that its stock price is 26% more volatile than the S&P 500. Comparatively, Opko Health has a beta of 1.82, suggesting that its stock price is 82% more volatile than the S&P 500.

Earnings and Valuation

This table compares Corium International and Opko Health’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Corium International $31.86 million 11.38 -$47.79 million ($1.67) -6.01
Opko Health $1.22 billion 2.32 -$25.08 million ($0.19) -26.68

Opko Health has higher revenue and earnings than Corium International. Opko Health is trading at a lower price-to-earnings ratio than Corium International, indicating that it is currently the more affordable of the two stocks.

Summary

Opko Health beats Corium International on 8 of the 14 factors compared between the two stocks.

About Corium International

Corium International, Inc. is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer’s disease. The Company has two transdermal platforms: Corplex for small molecules and MicroCor, a biodegradable microstructure technology for small molecules and biologics, including vaccines, peptides and proteins. Its late-stage pipeline includes a contraceptive patch, which has completed Phase III trials, and additional transdermal products that are being developed with other partners. Its products include Clonidine TDS, Fentanyl TDS and Crest Whitestrips. Its pipeline products include Twirla, Corplex Donepezil and Corplex Memantine, Donepezil, Corplex Ropinerole, MicroCor hPTH(1-34) and Motion Sickness Patch.

About Opko Health

OPKO Health, Inc. is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations. Through Bio-Reference, it operates laboratory divisions, such as Bio-Reference, GenPath (Oncology), GenPath (Women’s Health), GeneDx and Laboratorio Bueno Salud. As of December 31, 2016, it had one commercial stage pharmaceutical product and several pharmaceutical compounds and technologies in various stages of research and development for a range of indications and conditions, including Renal Products, Biologics, hGH-CTP, Factor VII, Oxyntomodulin, active pharmaceutical ingredients, Oligonucleotide Therapeutics, NK-1 Program, Asthma and chronic obstructive pulmonary disease.

Receive News & Ratings for Corium International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2018 Ticker Report. Google+.